We intend to post educational resources and news in Anaesthesia and Intensive care.
Labels
AIRWAY
(12)
ALGORITHMS
(201)
Antimicrobials
(2)
ARDS
(5)
Asthma
(1)
Brain injury
(6)
CARDIAC
(32)
CNS
(42)
COVID19
(6)
CVC
(1)
Death
(1)
DETERIORATING PATIENT
(16)
ELECTROLYTES
(4)
End of Life
(3)
ENDOCRINE
(8)
EVIDENCE BASED PRACTISE
(1)
FEVER
(3)
FLUID AND ELECTROLYTE
(6)
Fungal infections
(3)
GASTROENTEROLOGY
(22)
Haematology
(7)
Head Injury
(3)
HEPARIN
(1)
HEPATIC
(3)
HEPATIC FAILURE
(6)
HME
(2)
ICD
(4)
IHD
(7)
INFECTION
(5)
Insulin
(4)
labour epidural
(1)
LBBB
(2)
METABOLIC
(1)
MH
(1)
MI
(10)
nausea vomiting
(1)
Neurology
(7)
NEWSMAKERS
(1)
NIV
(3)
Nosocomial pneumonia
(3)
NUTRITION
(2)
Obstetrics and Gynaecology
(5)
Organ Donation
(1)
Pacemaker
(1)
Paediatrics
(3)
pancreatitis
(10)
PE
(5)
Percutaneous tracheostomy Video
(1)
perioperative
(3)
Physiology
(6)
PNEUMONIA
(3)
POST-OPERATIVE
(1)
Procedure
(4)
Procedure Video
(6)
pulmonary hypertension
(1)
RADIOLOGY
(8)
Recovery
(1)
Regional
(1)
REGIONAL ANAESTHESIA RESOURCES
(5)
Renal
(22)
RESPIRATORY
(18)
Resuscitation
(5)
RRT
(5)
Safety
(1)
Sedation
(1)
sepsis
(17)
SHOCK
(3)
sleep apnea
(1)
Spinal Anaesthesia
(1)
SPINE
(1)
Toxicology
(12)
Tracheostomy
(3)
Transfusion
(4)
TRAUMA
(10)
Travel
(2)
Vascular
(2)
VENTILATOR
(2)
Sunday, January 10, 2010
Valproate-Induced Hyperammonemic Encephalopathy
SpringerLink - Journal Article: "Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated, it has been associated with many neurological and systemic side effects. Among these, one of the most important is VPA-induced hyperammonemic encephalopathy (VHE): its typical signs are acute onset of impaired consciousness, focal neurologic symptoms, and increased seizure frequency."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: only a member of this blog may post a comment.